Sign In
Buy BDRX
$3.59
+0.0900 (+2.57%)
At Close: Jun 03, 2026
Biodexa issues letter to Shareholders
08:30am, Thursday, 14'th May 2026
May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or pre
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
08:30am, Thursday, 02'nd Apr 2026
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage
Preliminary Results for the Year Ended 31 December 2025
05:00pm, Friday, 27'th Mar 2026
March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Phar
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
08:30am, Monday, 23'rd Mar 2026
March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical sta
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Scheduled to Reverse Split on Monday, April 6th
01:14am, Saturday, 21'st Mar 2026
Shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX) are set to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The num
ADR Ratio Change
05:00pm, Wednesday, 18'th Mar 2026
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pip
Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)
02:08am, Monday, 16'th Mar 2026
Radiopharm Theranostics (NASDAQ: RADX - Get Free Report) and Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
08:30am, Monday, 09'th Mar 2026
March 9, 2026 Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX),
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
07:30am, Thursday, 19'th Feb 2026
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 20
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
08:30am, Wednesday, 04'th Feb 2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update
04:58am, Wednesday, 14'th Jan 2026
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totali
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
08:30am, Monday, 05'th Jan 2026
January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”),
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis
01:12am, Monday, 22'nd Dec 2025
Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will
Biodexa Announces Pricing of $10 Million Public Offering
08:30am, Thursday, 18'th Dec 2025
December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
08:30am, Monday, 01'st Dec 2025
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a cl
